Recent developments in receptor tyrosine kinases targeted anticancer therapy - Wikidata - wikimedia - TriplyDB

Recent developments in receptor tyrosine kinases targeted anticancer therapy

Recent developments in receptor tyrosine kinases targeted anticancer therapy

http://www.wikidata.org/entity/Q26751331

about

Germline Variants of Prostate Cancer in Japanese Families.Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation.Influences of Anlotinib on Cytochrome P450 Enzymes in Rats Using a Cocktail Method.

P2860

Q36152825-0030DE88-EDF7-46BE-9593-1BBE598BAADC Q42276494-0E9E2834-2629-4896-AE36-577F6DD5C2EB Q49449657-041F96F6-5510-4302-9C15-092123DA29D8

P2860

Recent developments in receptor tyrosine kinases targeted anticancer therapy

http://www.wikidata.org/entity/Q26751331

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@ast

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@en

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@nl

type

label

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@ast

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@en

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@nl

prefLabel

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@ast

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@en

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@nl

P1433

Q26751331-AEED5941-1B6D-467E-B69E-5B4D057A5D6C

P1476

Q26751331-692BA59E-31C7-46EC-A180-8E176399E657

P2093

Q26751331-12D2A26B-17EB-4964-8FA9-E5EEB01C4CED

Q26751331-948355D5-FE6C-4C48-865A-045E8B2B4F19

Q26751331-EA7682A9-862E-434B-820C-07B68202B991

Q26751331-F3BDE886-165D-43B4-B206-F8B30ED6CAED

P2860

Q26751331-02960624-9382-486D-92B6-56B43117AF4B

Q26751331-07DD3FE6-5A63-456A-A4B8-400A068A581E

Q26751331-0AF953C5-64DE-4CA1-9F43-36C7438410E0

Q26751331-0B6F33AC-EDB3-483E-B568-9C5A981ABCF7

Q26751331-0C5A7D1C-A2CE-4E34-BC92-21AE2B126D8D

Q26751331-0E8158D4-E340-41A8-9E82-7FFFC6B957AF

Q26751331-0FA99FFE-F08E-472A-8124-77A6CA84C0FE

Q26751331-12393962-3062-426B-BB7A-68AFB9EE421F

Q26751331-12FB3E41-2CE2-4138-BB1D-13EF7FE7A519

Q26751331-139F9F82-E624-4EF0-8228-0FB27F180B98

P304

Q26751331-EB7A9626-A6D2-43E3-8580-BC531EC4584B

P31

Q26751331-554D10D2-CE0A-4607-AEFA-02B136E9D3D7

P3181

Q26751331-2BCE7F8F-088C-4818-952F-663A70A6AA38

P356

Q26751331-33890C16-B471-47D1-8420-0AE3E866A990

P407

Q26751331-5CDE4AF4-8D13-4287-983B-887CE92332B6

P433

Q26751331-35A1EF6E-56EF-47D9-BDA1-D1D2A1EB7D2B

P478

Q26751331-AE955AD7-3398-4B18-89B0-AAD8F07A82AF

P50

Q26751331-2CAEAF1A-8A8E-4055-8B37-E784D03CE8BB

P577

Q26751331-9A82126D-2AD8-4940-8583-8C3E8BAF5D4B

P698

Q26751331-E5650D8F-8A3B-4999-9D8E-F017F346A354

P932

Q26751331-F8DA211A-5BDA-47D0-85DE-1AEEB9F9C5DE

P3181

P356

VETWORLD.2016.80-90

P1433

Veterinary world

P1476

Recent developments in receptor tyrosine kinases targeted anticancer therapy

@en

P2093

Dilip V Joshi

http://www.w3.org/2001/XMLSchema#string

Hitesh B Patel

http://www.w3.org/2001/XMLSchema#string

Samir H Raval

http://www.w3.org/2001/XMLSchema#string

Shailesh K Mody

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular signaling by fibroblast growth factor receptors

Cell signaling by receptor tyrosine kinases

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine

Tyrosine kinase - Role and significance in Cancer.

Progress of molecular targeted therapies for prostate cancers

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

P304

80-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3157227

http://www.w3.org/2001/XMLSchema#string

P356

10.14202/VETWORLD.2016.80-90

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27051190

http://www.w3.org/2001/XMLSchema#string

P932

4819356

http://www.w3.org/2001/XMLSchema#string